Start the conversation
In early January, we told you that Big Pharma players were starting the New Year with $70 billion in cash on their balance sheets - meaning the "buyout binge" that started in 2012 was certain to carry over into 2013.
And that's just what's happened.
Faced with patent expirations on existing blockbuster drugs, and pipelines that are bereft of replacements, Big Pharma players have been all year long to buy companies outright, to buy product lines or R&D portfolios, or just to purchase individual drugs.
This is premium content for Private Briefing subscribers only.